Alnylam Pharmace. Stock
Alnylam Pharmace. Stock
Alnylam Pharmace. gained 0.350% compared to yesterday.
The stock is an absolute favorite of our community with 50 Buy predictions and no Sell predictions.
Based on the current price of 189.65 € the target price of 426 € shows a potential of 124.62% for Alnylam Pharmace. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Alnylam Pharmace. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 0.350% | 6.396% | -32.653% | -49.210% | -44.023% | 13.156% | 14.281% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 319.835% | 171.194% |
| United Therapeutics | -0.580% | 3.809% | -5.572% | 81.464% | 9.057% | 115.541% | 156.044% |
| Ionis Pharmaceuticals Inc. | 1.990% | 8.773% | -35.384% | 39.931% | -28.119% | 37.451% | 47.985% |
Comments
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Truist Financial Corporation from $410.00 to $315.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) had its price target lowered by Citigroup Inc. from $380.00 to $340.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (ALNY) was upgraded by Raymond James Financial, Inc. from "outperform" to "strong-buy". They now have a $420.00 price target on the stock.
Show more
Ratings data for ALNY provided by MarketBeat